AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22050133 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (7 g)
Number of subjects: 10
Study 22050133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm)
Number of subjects: 25
Study 19931670 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin (20,000 ng/mL)
Number of subjects: 25
Study 19931670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide and prostacyclin
Number of subjects: 25
Study 16263778 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment/hospital setting (ATH)
Number of subjects: 466
Study 16263778 — intervention group
Group type: COMPARATOR
Intervention: Adequate symptom control/shared care setting (SCSC)
Number of subjects: 466
Study 15182981 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal walking trials (undisturbed)
Number of subjects: 20
Study 15182981 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed walking trials (lateral and anterior perturbations)
Number of subjects: 20
Study 15182981 — intervention group
Group type: COMPARATOR
Intervention: Initial contact joint angles
Number of subjects: 20
Study 15182981 — intervention group
Group type: COMPARATOR
Intervention: Sagittal plane excursion for hip and knee
Number of subjects: 20
Study 11421904 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichophyton extract skin test
Number of subjects: 86
Study 11421904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal culture for dermatophyte infection
Number of subjects: 86
Study 9493667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal inspiratory flow
Number of subjects: 8
Study 9493667 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inspiratory flow
Number of subjects: 8
Study 9493667 — intervention group
Group type: COMPARATOR
Intervention: Constant, sinusoidal, and decelerating inspiratory flow waveforms
Number of subjects: 8
Study 8422660 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 7.5 mg/kg twice a day
Number of subjects: 10
Study 8422660 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 5.0 mg/kg three times a day
Number of subjects: 10
Study 3775071 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 8 Gy
Number of subjects: 288
Study 3775071 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy in 10 daily fractions
Number of subjects: 288
Study 30055581 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcised men
Number of subjects: 0
Study 30055581 — intervention group
Group type: COMPARATOR
Intervention: Uncircumcised men
Number of subjects: 0
Study 27676362 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidimensional home-based exercise program integrating behavioral strategies
Number of subjects: 209
Study 27676362 — intervention group
Group type: COMPARATOR
Intervention: Promoting light-intensity activities of daily living (Control)
Number of subjects: 209
Study 25173802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 25173802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 0
Study 22411639 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac (30 mg)
Number of subjects: 34
Study 22411639 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl (25 μg)
Number of subjects: 34
Study 20558013 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood conduct problems during kindergarten
Number of subjects: 0
Study 20558013 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in childhood conduct problems over time
Number of subjects: 0
Study 20558013 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals classified into more problematic classes
Number of subjects: 0
Study 20558013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use and binge drinking during early adolescence
Number of subjects: 0
Study 17846853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g/day for 3 days
Number of subjects: 111
Study 17846853 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem 1 g/day for >=5 days
Number of subjects: 111
Study 15943731 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose preoperative antibiotics (group A)
Number of subjects: 269
Study 15943731 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose antibiotics (group B)
Number of subjects: 269
Study 15943731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day perioperative antibiotics (group C)
Number of subjects: 269
Study 12182212 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (8 mg orally twice a day)
Number of subjects: 8
Study 10485636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon, 10 mg
Number of subjects: 615
Study 10485636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon, 20 mg
Number of subjects: 615
Study 10485636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon, 5 mg
Number of subjects: 615
Study 10485636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem, 10 mg
Number of subjects: 615
Study 10485636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 615
Study 8601845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (1.3 g x kg‐1 x 24 h‐1)
Number of subjects: 20
Study 8601845 — intervention group
Group type: COMPARATOR
Intervention: Control (no amino acid infusion)
Number of subjects: 20
Study 8601845 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients (no amino acid infusion)
Number of subjects: 20
Study 1899682 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion starting at 0.2 microgram/kg/min, increased every 5 minutes by 0.1 to 0.2 microgram/kg/min until mean BP fell greater than 15 mm Hg or a dosage of 1.6 micrograms/kg/min was reached.
Number of subjects: 8
Study 1899682 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin-induced hypotension measurements.
Number of subjects: 8
Study 6751175 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month regimen of isoniazid, rifampicin, streptomycin, and pyrazinamide (SHRZ6)
Number of subjects: 444
Study 6751175 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month regimen of isoniazid, rifampicin, ethambutol, and pyrazinamide (EHRZ6)
Number of subjects: 444
Study 6751175 — intervention group
Group type: COMPARATOR
Intervention: 9-month regimen of isoniazid, rifampicin, and ethambutol (EHR9)
Number of subjects: 444
Study 31582542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-prednisone
Number of subjects: 654
Study 31582542 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide
Number of subjects: 654
Study 31582542 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan-prednisone-lenalidomide
Number of subjects: 654
Study 31582542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-prednisone-lenalidomide
Number of subjects: 654
Study 31582542 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide-dexamethasone
Number of subjects: 654
Study 30786186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg daily for up to 180 days)
Number of subjects: 841
Study 30786186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 30786186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg daily during intervention period)
Number of subjects: 841
Study 30786186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 841
Study 29045970 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 14
Study 29045970 — intervention group
Group type: COMPARATOR
Intervention: Patellar retention
Number of subjects: 14
Study 27079587 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroequatorial recession of horizontal rectus muscles
Number of subjects: 10
Study 27079587 — intervention group
Group type: COMPARATOR
Intervention: Hertle-Dell'Osso tenotomy procedure
Number of subjects: 10
Study 25041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-containing dressing (Remois Pad®) applied for 7 days
Number of subjects: 32
Study 25041310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dressing)
Number of subjects: 32
Study 25041310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-containing dressing (Remois Pad®)
Number of subjects: 32
Study 23042893 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-centered instruction
Number of subjects: 0
Study 23042893 — intervention group
Group type: COMPARATOR
Intervention: Teacher-centered instruction
Number of subjects: 0
Study 20031857 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 20031857 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0
Study 18236908 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg of drotaverine hydrochloride intravenously at >= 3cm dilatation of the cervix
Number of subjects: 200
Study 18236908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drotaverine)
Number of subjects: 200
Study 18236908 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg of drotaverine hydrochloride intravenously
Number of subjects: 200
Study 15188337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg/day or less in case of renal insufficiency) and plasma exchanges (3/week for 3 weeks, 2/week for 2 weeks, then 1/week until seroconversion or clinical recovery) after short-term corticosteroids (oral prednisone 1 mg/kg/day for 1 week, then tapered and withdrawn within 1 week).
Number of subjects: 10
Study 15188337 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term corticosteroids followed by lamivudine and plasma exchanges.
Number of subjects: 10
Study 11490380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtube (Group T)
Number of subjects: 80
Study 11490380 — intervention group
Group type: COMPARATOR
Intervention: No overtube (Group NT)
Number of subjects: 80
Study 9580391 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1: 200 ml 0.1N citric acid solution 10 min before 75 mg 13C-urea
Number of subjects: 40
Study 9580391 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2: 200 ml 0.1N citric acid solution simultaneously with 75 mg 13C-urea
Number of subjects: 40
Study 8061726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg plus caffeine 200 mg (EC)
Number of subjects: 32
Study 8061726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2498931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.0 mg PO)
Number of subjects: 0
Study 2498931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.3 mg, 1.0 mg, or 3.0 mg IV)
Number of subjects: 0
Study 2498931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4629075 — intervention group
Group type: EXPERIMENTAL
Intervention: Live adenovirus type 21 vaccine
Number of subjects: 15
Study 4629075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 29876777 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (3.0 × 10^8 CFU/g Streptococcus thermophilus MG510 and 1.0 × 10^8 CFU/g Lactobacillus plantarum LRCC5193) daily for 4 weeks
Number of subjects: 171
Study 29876777 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 171
Study 29876777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 28116880 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI for 15 minutes at 14 °C
Number of subjects: 105
Study 28116880 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI for 5 minutes at 14 °C
Number of subjects: 105
Study 28116880 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI (all forms)
Number of subjects: 105
Study 28116880 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 105
Study 24646336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion discontinued at the onset of active labor (5cm cervical dilatation)
Number of subjects: 140
Study 24646336 — intervention group
Group type: COMPARATOR
Intervention: Incremental oxytocin infusion maintained until delivery
Number of subjects: 140
Study 24646336 — intervention group
Group type: COMPARATOR
Intervention: Both groups (study and control)
Number of subjects: 140
Study 24121096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) plus drug withdrawal
Number of subjects: 70
Study 24121096 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo biofeedback (PL) plus drug withdrawal
Number of subjects: 70
Study 24121096 — intervention group
Group type: COMPARATOR
Intervention: Drug withdrawal (MED) only
Number of subjects: 70
Study 21219287 — intervention group
Group type: EXPERIMENTAL
Intervention: 1½-h daylight exposure
Number of subjects: 120
Study 21219287 — intervention group
Group type: COMPARATOR
Intervention: 2½-h daylight exposure
Number of subjects: 120
Study 18496246 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy + hot packs and isokinetic exercise
Number of subjects: 100
Study 18496246 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation + hot packs and isokinetic exercise
Number of subjects: 100
Study 18496246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound + hot packs and isokinetic exercise
Number of subjects: 100
Study 18496246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot packs and isokinetic exercise
Number of subjects: 100
Study 18496246 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic exercise only
Number of subjects: 100
Study 16461125 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT with Alutard SQ grass pollen
Number of subjects: 39
Study 16461125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15303313 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone 2.5 mg/day (n = 6)
Number of subjects: 15
Study 15303313 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (n = 9)
Number of subjects: 15
Study 11782264 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise program
Number of subjects: 38
Study 11782264 — intervention group
Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 38
Study 11782264 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training regime (second study)
Number of subjects: 38
Study 9314976 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase shift contrast agent
Number of subjects: 25
Study 9314976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 8218099 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma t‐PA antigen (t‐PA:ag) levels
Number of subjects: 633
Study 3315932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (n = 15)
Number of subjects: 25
Study 3315932 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (n = 13)
Number of subjects: 25
Study 3315932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 29230803 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 150
Study 29230803 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 150
Study 29230803 — intervention group
Group type: COMPARATOR
Intervention: Insulin bolus
Number of subjects: 150
Study 28339831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting higher ferritin (400-600 µg/L)
Number of subjects: 616
Study 28339831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting lower ferritin (100-200 µg/L)
Number of subjects: 616
Study 28339831 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 616
Study 26252381 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom training based on the school manual
Number of subjects: 3293
Study 26252381 — intervention group
Group type: COMPARATOR
Intervention: Leaflet on climate change and health issues
Number of subjects: 3293
Study 24363619 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 134
Study 24363619 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 134
Study 20332194 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 h prophylactic antibiotic therapy
Number of subjects: 235
Study 20332194 — intervention group
Group type: COMPARATOR
Intervention: 72 h prophylactic antibiotic therapy
Number of subjects: 235
Study 17904899 — intervention group
Group type: EXPERIMENTAL
Intervention: Various practice management systems (PMS) used to measure immunisation coverage
Number of subjects: 124
Study 18603948 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian perivascular approach (Group I, n=30)
Number of subjects: 60
Study 18603948 — intervention group
Group type: COMPARATOR
Intervention: Parascalene approach (Group II, n=30)
Number of subjects: 60
Study 14515575 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-loaded restorations
Number of subjects: 30
Study 14515575 — intervention group
Group type: COMPARATOR
Intervention: 2-stage-unloaded healing approaches
Number of subjects: 30
Study 10773717 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tar shampoo (2% salicylic acid, 0.75% piroctone olamine, 0.5% elubiol)
Number of subjects: 30
Study 10773717 — intervention group
Group type: COMPARATOR
Intervention: Coal tar shampoo (0.5%)
Number of subjects: 30
Study 9678121 — intervention group
Group type: EXPERIMENTAL
Intervention: No-scalpel technique
Number of subjects: 1203
Study 9678121 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 1203
Study 1505155 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 79
Study 1505155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 79
Study 1505155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 6208103 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission induction treatment with Ara‐C c. inf. from the first to the eighth day plus Adr. from the first to the third day
Number of subjects: 100
Study 6208103 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission induction treatment with Ara‐C + 6‐TG + Adr., 6 + 6 + 2 days
Number of subjects: 100
Study 6208103 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 5 day course of Ara‐C s.c. in addition to 6‐TG, Vincristine plus Prednisone and Adriamycin
Number of subjects: 100
Study 6208103 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf thymus extract (TFX‐Polfa) in addition to maintenance therapy
Number of subjects: 100
Study 31083077 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-111 (0.4 mg/ml)
Number of subjects: 256
Study 31083077 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-111 (0.8 mg/ml)
Number of subjects: 256
Study 31083077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 30071702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored communication regarding patients' oral health based on health literacy levels
Number of subjects: 133
Study 30071702 — intervention group
Group type: COMPARATOR
Intervention: Brief information not tailored to health literacy levels (Control)
Number of subjects: 133
Study 26936841 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 307
Study 26936841 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 307
Study 24814751 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 117
Study 24814751 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 117
Study 22863642 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use
Number of subjects: 2562
Study 22863642 — intervention group
Group type: EXPERIMENTAL
Intervention: High supplement users (≥3 formulations per day)
Number of subjects: 2562
Study 22863642 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 2562
Study 18803557 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (EMLA 5% cream)
Number of subjects: 50
Study 18803557 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 50
Study 18036295 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 583
Study 18036295 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 583
Study 18036295 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation or antiplatelet drugs
Number of subjects: 583
Study 18036295 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of stroke
Number of subjects: 583
Study 16315032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aqueous timolol
Number of subjects: 37
Study 16315032 — intervention group
Group type: COMPARATOR
Intervention: 0.1% hydrogel timolol
Number of subjects: 37
Study 16315032 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test
Number of subjects: 37
Study 16315032 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum exercise test
Number of subjects: 37
Study 11862356 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 50
Study 11862356 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 50
Study 11862356 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 600 mg
Number of subjects: 50
Study 11862356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10203414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic group (800 mg twice daily of oral clodronate for 2 weeks every 3 months for the first 12 months)
Number of subjects: 54
Study 10203414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group (400 mg of clodronate once daily for the second 12 months)
Number of subjects: 54
Study 10203414 — intervention group
Group type: COMPARATOR
Intervention: Cyclic group (placebo for the second 12 months)
Number of subjects: 54
Study 10203414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54